| # | Title | Journal | Year | Citations |
|---|
| 1 | Inflammation and cancer | Nature | 2002 | 12,666 |
| 2 | Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis | Nature Cell Biology | 2000 | 2,487 |
| 3 | The role of pericytes in blood-vessel formation and maintenance | Neuro-Oncology | 2005 | 1,252 |
| 4 | Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate Cancer | Journal of Clinical Oncology | 2006 | 1,004 |
| 5 | 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4) | Annals of Oncology | 2018 | 891 |
| 6 | 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) | Annals of Oncology | 2017 | 865 |
| 7 | 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) | Annals of Oncology | 2020 | 761 |
| 8 | Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies | Molecular Cancer | 2006 | 635 |
| 9 | A tiling resolution DNA microarray with complete coverage of the human genome | Nature Genetics | 2004 | 597 |
| 10 | PDGFRβ+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival | Nature Cell Biology | 2005 | 518 |
| 11 | The genetics and genomics of cancer | Nature Genetics | 2003 | 495 |
| 12 | VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex | Cancer Cell | 2012 | 495 |
| 13 | Antiandrogen Withdrawal Alone or in Combination With Ketoconazole in Androgen-Independent Prostate Cancer Patients: A Phase III Trial (CALGB 9583) | Journal of Clinical Oncology | 2004 | 464 |
| 14 | ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) | Annals of Oncology | 2014 | 402 |
| 15 | Liposome-based drug delivery in breast cancer treatment | Breast Cancer Research | 2002 | 392 |
| 16 | A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer | Clinical Cancer Research | 2007 | 385 |
| 17 | Extent of Disease at Presentation and Outcome for Adrenocortical Carcinoma: Have We Made Progress? | World Journal of Surgery | 2006 | 372 |
| 18 | The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade | Journal of Pathology | 2010 | 369 |
| 19 | Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers | Gynecologic Oncology | 2008 | 359 |
| 20 | Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity | Cancer Cell | 2004 | 342 |
| 21 | The many ways to cleave hyaluronan | Biotechnology Advances | 2007 | 336 |
| 22 | Combined Analysis of Two Multicenter, Randomized, Placebo-Controlled Studies of Pamidronate Disodium for the Palliation of Bone Pain in Men With Metastatic Prostate Cancer | Journal of Clinical Oncology | 2003 | 328 |
| 23 | Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human | Nature Genetics | 2003 | 310 |
| 24 | Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas | Cancer | 2008 | 304 |
| 25 | Natural History of Stage I Non-Small Cell Lung Cancer | Chest | 2007 | 302 |
| 26 | The Changing Face of Prostate Cancer | Journal of Clinical Oncology | 2005 | 293 |
| 27 | Stromal cells can contribute oncogenic signals | Seminars in Cancer Biology | 2001 | 291 |
| 28 | 1st International consensus guidelines for advanced breast cancer (ABC 1) | Breast | 2012 | 291 |
| 29 | Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1 | Annals of Oncology | 2021 | 279 |
| 30 | Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1α | Genes and Development | 2001 | 275 |
| 31 | ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) | Breast | 2014 | 269 |
| 32 | Stem-cell hierarchy in skin cancer | Nature Reviews Cancer | 2003 | 261 |
| 33 | Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study | Annals of Oncology | 2018 | 261 |
| 34 | Society of Gynecologic Oncologists Education Committee Statement on Risk Assessment for Inherited Gynecologic Cancer Predispositions☆ | Gynecologic Oncology | 2007 | 257 |
| 35 | Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial | Lancet Oncology, The | 2022 | 237 |
| 36 | Targeting HER proteins in cancer therapy and the role of the non-target HER3 | British Journal of Cancer | 2007 | 234 |
| 37 | NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2011 | 227 |
| 38 | Future directions of liposome- and immunoliposome-based cancer therapeutics | Seminars in Oncology | 2004 | 223 |
| 39 | Single-Cell Profiling Identifies Aberrant STAT5 Activation in Myeloid Malignancies with Specific Clinical and Biologic Correlates | Cancer Cell | 2008 | 219 |
| 40 | c-Jun Is Essential for Organization of the Epidermal Leading Edge | Developmental Cell | 2003 | 208 |
| 41 | Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study | The Lancet Gastroenterology and Hepatology | 2021 | 205 |
| 42 | Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers | British Journal of Cancer | 2011 | 195 |
| 43 | HSulf-2, an extracellular endoglucosamine-6-sulfatase, selectively mobilizes heparin-bound growth factors and chemokines: effects on VEGF, FGF-1, and SDF-1 | BMC Biochemistry | 2006 | 192 |
| 44 | Distinguishing melanocytic nevi from melanoma by DNA copy number changes: comparative genomic hybridization as a research and diagnostic tool | Dermatologic Therapy | 2006 | 186 |
| 45 | De Novo Infection and Serial Transmission of Kaposi's Sarcoma-Associated Herpesvirus in Cultured Endothelial Cells | Journal of Virology | 2002 | 185 |
| 46 | Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents | Cancer Cell | 2002 | 183 |
| 47 | Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway | Cancer Research | 2002 | 179 |
| 48 | High-risk prostate cancer in the United States, 1990–2007 | World Journal of Urology | 2008 | 173 |
| 49 | 3rd ESO–ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3) | Breast | 2017 | 171 |
| 50 | Genomic Predictors of Outcome in Prostate Cancer | European Urology | 2015 | 166 |
